AstraZeneca and Daiichi Sankyo announce clinical collaboration with Summit Therapeutics

AZN•2026-10-02

AstraZeneca, Daiichi Sankyo and Summit Therapeutics will collaborate on a Phase III trial of Datroway in first-line triple-negative breast cancer; each company will contribute medicine and trial costs and retain rights.

AstraZeneca and Daiichi Sankyo announce clinical collaboration with Summit Therapeutics

1. Phase III trial

Related News

Asian shares fall after wild swings in bonds, FX; US jobs data looms

Broadcom reportedly starts amassing $60 billion to fund chips for Anthropic

First new F-16V fighter jets to arrive in Taiwan to bolster defenses against China

Truist Financial Corporation: JPMorgan cuts target price to $50.5 from $54

Independent Bank Corp: Piper Sandler raises to overweight from neutral